Harnessing the immune response for cancer detection

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 4, 2011, Pages 569-570

  Hanash, Samir ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN;

ANTIGEN ANTIBODY REACTION; AUTOIMMUNITY; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY;

EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS;

EID: 79955784911     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0183     Document Type: Note

References (7)

1. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60:4000-4. (Pubitemid 30636572)
2. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-6.
3. Li Y, Karjalainen A, Koskinen H, Hemminki K, Vainio H, Shnaidman M, et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005;114:157-60. (Pubitemid 40194322)
4. Qiu J, Hanash S. Autoantibody profiling for cancer detection. Clin Lab Med 2009;29:31-46.
5. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009;58:1535-44.
6. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.
7. Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003;198:1623-6. (Pubitemid 37494154)